Isbn: 9789401083478 - human insulin: clinical pharmacological studies in normal man (9 risultati)

Perfeziona la tua ricerca

  • Libri (9)

a

Fascia di prezzo personalizzata (EUR)

a

  • Lingua: Inglese

    Editore: Springer 2013-10-04, 2013

    9401083479 / 9789401083478

    • Brossura

    Da: Chiron Media, Wallingford, Regno UnitoChiron Media

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 57,39

    EUR 18,07 spedizione 
    Spedito da Regno Unito a U.S.A.

    Quantità: 10 disponibili

    Paperback. Condizione: New.

  • Lingua: Inglese

    Editore: Springer, 2011

    9401083479 / 9789401083478

    • Brossura

    Da: Ria Christie Collections, Uxbridge, Regno UnitoRia Christie Collections

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 67,17

    EUR 13,17 spedizione 
    Spedito da Regno Unito a U.S.A.

    Quantità: Più di 20 disponibili

    Condizione: New. In English.

  • Lingua: Inglese

    Editore: Springer, 2011

    9401083479 / 9789401083478

    • Brossura

    Da: Revaluation Books, Exeter, Regno UnitoRevaluation Books

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 80,54

    EUR 11,67 spedizione 
    Spedito da Regno Unito a U.S.A.

    Quantità: 2 disponibili

    Paperback. Condizione: Brand New. 308 pages. 9.25x6.10x0.70 inches. In Stock.

  • Lingua: Inglese

    Editore: Springer, Springer, 2011

    9401083479 / 9789401083478

    • Brossura

    Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 61,97

    EUR 35,00 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 1 disponibile

    Taschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - Since insulin became available for the treatment of diabetes in 1922 a number of major advances have been made, which include the modification of insulin to vary its timing of action, its purification, and latterly, the production of human insulin. Human insulin in quantities sufficiently large for therapy has been made available by two techniques developed in parallel during the late 1970s. These involve either (i) formulation in E. coli bacteria suitably encoded by DNA recombinant methods of the A- and B-chains of human insulin followed by a chain combination reaction ('biosynthetic' human insulin) or (ii) enzymatic conversion (transpeptidation) of porcine insulin brought to react with a threonine ester by porcine trypsin in a mixture of water and organic solvents, yielding human insulin ('semi-synthetic' human insulin). This book includes the first clinical-pharmacological studies of each of the highly purified 'semi-synthetic' human insulin preparations: Actrapid ® HM; Monotard® HM; Protaphane® HM; Actraphane® HM; and Ultratard® HM (Novo Industri A/S, Copenhagen). The preliminary studies established their safety and efficacy relative to their porcine and bovine counterparts emphasising the relevance of species and formulation on the pharmacokinetics and biological responses to insulin. Additional investigations with human insulin demonstrated the influence of insulin concentration, site of administration, the addition of aprotinin to insulin and the mixing of 'short-' and 'intermediate-acting' formulations on insulin 'bioavailability'. Examination of the 'within' and 'between' subject day-to-day variation in absorption and the effect of subcutaneous insulin also demonstrates the dominating influence of insulin responsiveness. …

  • Lingua: Inglese

    Editore: Springer, 2011

    9401083479 / 9789401083478

    • Brossura

    Da: Mispah books, Redhill, SURRE, Regno UnitoMispah books

    Venditore con 4 stelle
    Contatta il venditore

    Condizione: Usato - Come nuovo

    EUR 127,37

    EUR 29,17 spedizione 
    Spedito da Regno Unito a U.S.A.

    Quantità: 1 disponibile

    Paperback. Condizione: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

  • Lingua: Inglese

    Editore: Springer, 2011

    9401083479 / 9789401083478

    • Brossura
    • Print on Demand

    Da: Brook Bookstore On Demand, Napoli, NA, ItaliaBrook Bookstore On Demand

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 46,22

    EUR 5,50 spedizione 
    Spedito da Italia a U.S.A.

    Quantità: Più di 20 disponibili

    Condizione: new. Questo è un articolo print on demand.

  • Lingua: Inglese

    Editore: Springer Netherlands Okt 2011, 2011

    9401083479 / 9789401083478

    • Brossura
    • Print on Demand

    Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermaniaBuchWeltWeit Ludwig Meier e.K.

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 53,49

    EUR 23,00 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 2 disponibili

    Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Since insulin became available for the treatment of diabetes in 1922 a number of major advances have been made, which include the modification of insulin to vary its timing of action, its purification, and latterly, the production of human insulin. Human insulin in quantities sufficiently large for therapy has been made available by two techniques developed in parallel during the late 1970s. These involve either (i) formulation in E. coli bacteria suitably encoded by DNA recombinant methods of the A- and B-chains of human insulin followed by a chain combination reaction ('biosynthetic' human insulin) or (ii) enzymatic conversion (transpeptidation) of porcine insulin brought to react with a threonine ester by porcine trypsin in a mixture of water and organic solvents, yielding human insulin ('semi-synthetic' human insulin). This book includes the first clinical-pharmacological studies of each of the highly purified 'semi-synthetic' human insulin preparations: Actrapid ® HM; Monotard® HM; Protaphane® HM; Actraphane® HM; and Ultratard® HM (Novo Industri A/S, Copenhagen). The preliminary studies established their safety and efficacy relative to their porcine and bovine counterparts emphasising the relevance of species and formulation on the pharmacokinetics and biological responses to insulin. Additional investigations with human insulin demonstrated the influence of insulin concentration, site of administration, the addition of aprotinin to insulin and the mixing of 'short-' and 'intermediate-acting' formulations on insulin 'bioavailability'. Examination of the 'within' and 'between' subject day-to-day variation in absorption and the effect of subcutaneous insulin also demonstrates the dominating influence of insulin responsiveness. 308 pp. Englisch. …

  • Lingua: Inglese

    Editore: Springer Netherlands, 2011

    9401083479 / 9789401083478

    • Brossura
    • Print on Demand

    Da: moluna, Greven, Germaniamoluna

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 48,37

    EUR 48,99 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: Più di 20 disponibili

    Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Since insulin became available for the treatment of diabetes in 1922 a number of major advances have been made, which include the modification of insulin to vary its timing of action, its purification, and latterly, the production of human insulin. Human in. …

  • Lingua: Inglese

    Editore: Springer, Springer Okt 2011, 2011

    9401083479 / 9789401083478

    • Brossura
    • Print on Demand

    Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germaniabuchversandmimpf2000

    Venditore con 5 stelle
    Contatta il venditore

    Condizione: Nuovo

    EUR 53,49

    EUR 60,00 spedizione 
    Spedito da Germania a U.S.A.

    Quantità: 1 disponibile

    Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Since insulin became available for the treatment of diabetes in 1922 a number of major advances have been made, which include the modification of insulin to vary its timing of action, its purification, and latterly, the production of human insulin. Human insulin in quantities sufficiently large for therapy has been made available by two techniques developed in parallel during the late 1970s. These involve either (i) formulation in E. coli bacteria suitably encoded by DNA recombinant methods of the A- and B-chains of human insulin followed by a chain combination reaction ('biosynthetic' human insulin) or (ii) enzymatic conversion (transpeptidation) of porcine insulin brought to react with a threonine ester by porcine trypsin in a mixture of water and organic solvents, yielding human insulin ('semi-synthetic' human insulin). This book includes the first clinical-pharmacological studies of each of the highly purified 'semi-synthetic' human insulin preparations: Actrapid ® HM; Monotard® HM; Protaphane® HM; Actraphane® HM; and Ultratard® HM (Novo Industri A/S, Copenhagen). The preliminary studies established their safety and efficacy relative to their porcine and bovine counterparts emphasising the relevance of species and formulation on the pharmacokinetics and biological responses to insulin. Additional investigations with human insulin demonstrated the influence of insulin concentration, site of administration, the addition of aprotinin to insulin and the mixing of 'short-' and 'intermediate-acting' formulations on insulin 'bioavailability'. Examination of the 'within' and 'between' subject day-to-day variation in absorption and the effect of subcutaneous insulin also demonstrates the dominating influence of insulin responsiveness.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 308 pp. Englisch.…